Altamira Therapeutics (FRA:2QA) LT-Debt-to-Total-Asset: 0.03 (As of Jun. 2025)


FRA:2QA Altamira Therapeutics Ltd FRA:2QA
30 GF Score
Price €948.00
! 4 Warning Signs
View Full Analysis

What is Altamira Therapeutics LT-Debt-to-Total-Asset?

Altamira Therapeutics FRA:2QA 30 LT-Debt-to-Total-Asset is 0.03 as of Jun. 2025. GuruFocus rates FRA:2QA with a GF Score™ of 30/100. The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Altamira Therapeutics's long-term debt to total assests ratio for the quarter that ended in Jun. 2025 was 0.03.

Altamira Therapeutics's long-term debt to total assets ratio declined from Jun. 2024 (0.04) to Jun. 2025 (0.03). It may suggest that Altamira Therapeutics is progressively becoming less dependent on debt to grow their business.

Altamira Therapeutics  (FRA:2QA) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Altamira Therapeutics LT-Debt-to-Total-Asset Related Terms

Altamira Therapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Altamira Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Altamira Therapeutics LT-Debt-to-Total-Asset Chart

Altamira Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.02 0.05 0.00 0.03

Altamira Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.00 0.04 0.03 0.03
FRA:2QA
30GF Score
Altamira Therapeutics Ltd FRA:2QA
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Altamira Therapeutics LT-Debt-to-Total-Asset Calculation

Altamira Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )/Total Assets (A: Dec. 2024 )
=0.228/8.263
=

Altamira Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2025 is calculated as

LT Debt to Total Assets (Q: Jun. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2025 )/Total Assets (Q: Jun. 2025 )
=0.173/6.182
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.03 mean?
Altamira Therapeutics (FRA:2QA) has a LT-Debt-to-Total-Asset of 0.03 as of Jun. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Altamira Therapeutics and its competitors.
Is Altamira Therapeutics' LT-Debt-to-Total-Asset too high?
Altamira Therapeutics' current LT-Debt-to-Total-Asset is 0.03. Overall, Altamira Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Altamira Therapeutics' LT-Debt-to-Total-Asset compare to IOBTQ and SCPX?
Altamira Therapeutics' LT-Debt-to-Total-Asset of 0.03 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Altamira Therapeutics and its competitors. Altamira Therapeutics's current LT-Debt-to-Total-Asset is 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Altamira Therapeutics stock overvalued right now?
Altamira Therapeutics (FRA:2QA) has a current LT-Debt-to-Total-Asset of 0.03. The current LT-Debt-to-Total-Asset is 0.03. Altamira Therapeutics' overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Altamira Therapeutics (FRA:2QA), the current LT-Debt-to-Total-Asset is 0.03 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Altamira Therapeutics Business Description

Other Exchanges CYTOF:USA
Address 2 Church Street, Clarendon House, Hamilton, BMU, HM11
Altamira Therapeutics Ltd is developing and supplying peptide-based nanoparticles for safe and effective RNA delivery to extrahepatic tissues (xPhore platform). The Company is offering biopharmaceutical companies access to its technology for use with their own RNA molecules under collaboration and licensing agreements. The xPhore platform is suitable for various RNA modalities - OligoPhore for oligonucleotides, SemaPhore for mRNA, CycloPhore for circRNA - as well as for DNA (GenePhore). In addition, Altamira Therapeutics is pursuing two proprietary flagship development programs using OligoPhore: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. Geographically, the companies operates in United Staes and Switzerland.
30GF Score

Get the complete analysis for FRA:2QA

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€948.00
Price